PMS57 Cost-Effectiveness Analysis of Bisphosphonates for Secondary Prevention of Hip Fracture In Taiwan  by Lo, P. et al.
A162  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  
treatments only, in the patient care pathway. The sequence of biologics treatments 
used in both cases is: Infliximab, Adalimumab, Tocilizumab, Rituximab, Etanercept 
and salvage therapy, according to experts opinion from MINSA [2]. All patients 
received concomitant treatment with methotrexate. The characteristics included 
in model are: age, weight, initial HAQ score, severe adverse events (SAE) and clini-
cal response to short and long term treatment; randomized controlled trials were 
used as source information when local information was not available [3,4]. HAQ 
scores were used to calculate utilities, measured in QALYs [5,6,7]. Only direct costs 
were considerate from MINSA databases of 2014 [8]. A lifetime horizon time was 
used with an annual discount rate of 5%. RESULTS: Total cost and total QALY per 
patient in a lifetime period are $193,971 and 9.28 QALY for treatment sequence 
with Tofacitinib; $205,015 and 9.20 for treatment sequence with biologic therapy. 
The cost saving for treatment sequence with Tofacitinib in years one, five and ten 
were: 12%, 10%, 8% respectively. CONCLUSIONS: In case of MINSA, the sequence 
initiating with Tofacitinib is a cost-saving alternative compared with biologic 
therapy.
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OBJECTIVES: Progression of PsA can lead to irreversible damage, functional impair-
ment, and associated healthcare costs. Anti-TNF biologics have been shown to delay 
PsA progression and seem to have better efficacy compared with apremilast, a phos-
phodiesterase-4 inhibitor recently approved for PsA. The impact of using apremilast 
prior to anti-TNF has not been fully understood. This study evaluated the economic 
impacts of timely versus delayed use of anti-TNF among patients with moderately-
to-severely active PsA from a US payer perspective. METHODS: A Markov model 
was developed to evaluate the costs and outcomes of two treatment sequences over 
a one-year time horizon. PsA patients received either adalimumab (timely use of 
anti-TNF) or apremilast (delayed use) as initial treatment. Those who did not achieve 
ACR20 response in the first 12 weeks of treatment or who lost ACR20 response 
would use subsequent treatments, which included a mixture of anti-TNF biologics, 
followed by palliative care. Efficacy was based on ACR20 response, changes in the 
Health Assessment Questionnaire (HAQ), and reduction in skin lesions measured 
by the Psoriasis Area and Severity Index (PASI). Direct costs, including treatment-
related costs and other medical costs, and incremental costs per responder were 
calculated. Subgroup analyses among patients with moderate-to-severe psoriasis 
were performed. RESULTS: After one year, patients starting with adalimumab had 
higher ACR20 response rates and higher costs than apremilast (70.4% vs. 59.6%, 
$37,732 vs. $31,173). The one-year incremental cost per ACR20 responder was 
$60,766 for timely vs. delayed use of anti-TNF. Among the subgroup with psoriasis, 
starting with adalimumab lead to higher response rates in both ACR20 and PASI75 
and higher costs compared with apremilast (43.2% vs. 30.0%, $39,329 vs. $33,143). 
The incremental cost per ACR20+PASI75 responder was $46,949. CONCLUSIONS: 
Timely use of anti-TNF is a cost-effective strategy for the management of PsA due 
to improvements in joint and skin condition.
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OBJECTIVES: This study aims to perform a cost-effectiveness analysis of biologic 
alternatives for rheumatoid arthritis (RA), psoriasis (PSO) and ankylosing spon-
dylitis (AS) in Brazil, from public and private perspectives. METHODS: A deci-
sion tree model was developed for AR and PSO to evaluate the cost-effectiveness 
of biological drugs (etanercept, adalimumab, infliximab, tocilizumab, abatacept 
and rituximab). Effectiveness measures were extracted from literature and out-
comes included: ACR20 and ACR70 responses, and HQA for RA; and PASI 75 suc-
cess rate for PSO. Only costs were compared for AS because the model assumed 
the same effectiveness for drugs, according to literature review. Direct medical 
costs included biological acquisition, adverse events management and infusion 
(if applicable), presented in 2014 BRL. RESULTS: From the public perspective, in 
AR, etanercept was the most cost-effective option when compared to others drugs 
for all measures (158,731 BRL for ACR20, 282,448 BRL for ACR70 and 121,946 BRL for 
HAQ), followed by adalimumab, infliximab and tocilizumab, and rituximab. The 
same result was observed for PSO. Etanercept showed a cost-effectiveness ratio 
per PASI 75 response of 104,820 BRL versus 110,886 BRL for adalimumab. From the 
private perspective, once again etanercept was the most cost-effective option 
for all evaluated diseases. In RA, the cost-effectiveness ratios per ACR20, ACR70 
and HAQ were 193,211 BRL, 343,802 BRL, 148,435 BRL, respectively, and in PSO the 
value observed per PASI 75 response was 133,871 BRL versus 179,607 BRL for adali-
mumab and 268,504 BRL for infliximab. In AS, from both perspectives, etanercept 
represented the least costly option: 55,581 BRL versus 69,602 BRL for infliximab 
(public); 70,985 BRL versus 75,435 BRL for adalimumab and 99,883 BRL for inflixi-
mab (private). CONCLUSIONS: Etanercept showed the best cost-effectiveness ratio 
and lower costs when compared to others biological drugs in the management of 
AR, PSO and AS, from both Brazilian perspectives.
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rate-cost-age curve at 70yo prompted further consideration. Markov analysis indi-
cated the cost-effective CoP revision rate to be 12.5 revisions/100THAs at $325 cost 
difference and 9.0/100THAs at $1,003 cost difference, in a 70yo patient, indicating 
that CoP can be cost-effective. CONCLUSIONS: Shifting from MoP to CoP can be 
justified depending on the patient age, cost of the device, and actual CoP revision 
rate. All else equal, shifting all THAs in patients below age 70 to CoP and over 70 to 
MoP can be cost justified, even in the highest cost difference case.
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OBJECTIVES: Etanercept (ETA), certolizumab (CZP) and golimumab (GLM), each 
in combination with methotrexate (MTX) are the currently indicated treatment 
regimen for moderate to severe rheumatoid arthritis (RA). Recently, a novel oral 
agent, tofacitinib (CP-690550), was approved to treat RA. This study assesses the 
relative costs and effectiveness of these four disease modifying antirheumatic drugs 
(DMARDs) from a societal perspective. METHODS: We developed a Markov model 
that tracked a cohort of patients through the four disease states of RA progression, 
defined based on the patients’ disease activity score (DAS28). We estimated each 
drug’s effectiveness from published head-to-head clinical trial data. We derived 
quality of life utility scores and costs data for each disease state from the published 
literature. For each agent, we estimated the discounted costs, quality-adjusted life 
years (QALYs) and incremental cost-effectiveness ratios (ICERs). Univariate sensi-
tivity analyses were conducted to assess the impact of parameter uncertainty on 
our results. RESULTS: Relative to other drugs, and at the average US societal will-
ingness to pay (WTP) threshold of $150,000/QALY gained, ETA+MTX was the most 
cost-effective treatment regimen, with an ICER of $US 15,670/QALY gained when 
compared with CZP+MTX. The novel oral agent, CP-690550, was also relatively cost-
effective, with an ICER of $US 31,643/QALY gained relative to CZP+MTX. GLM+MTX 
was not deemed cost-effective ($239,000/QALY gained) relative to all other regimens, 
at the conventional US WTP threshold. Sensitivity analyses showed that results were 
very sensitive to the costs of each treatment. CONCLUSIONS: ETA+MTX is the most 
cost-effective treatment for moderate to severe RA in US patients. Compared to 
CZP+MTX, the novel oral agent, CP-690550, is also highly cost-effective. GLM+MTX 
is not cost-effective.
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OBJECTIVES: To compare health outcomes and costs associated with a treatment 
sequence that includes tofacitinib with another treatment sequence without tofaci-
tinib in patients with Rheumatoid Arthritis (RA) who failed to DMARDS from the 
payer’s perspective of the Ministry of public healthcare in Ecuador. METHODS: We 
compared with an Excel-based patient level simulation model, in a lifetime horizon, 
two treatment sequences, 1) treatment sequence: includes the use of tofacitinib, 
etanercept, adalimumab, tocilizumab, rituximab and salvage therapy, 2) compara-
tor sequence: includes the use of adalimumab, etanercept, inflximab, tocilizumab, 
rituximab and salvage therapy. All patients modeled received concomitant treat-
ment with methotrexate. Based on the available randomized controlled trials, HAQ 
score and clinical response to short and long term treatment data were obtained to 
calculate utilities, which were measured in QALYs. All costs information 2014 (drug 
and adverse events) were obtained from public data sources of the Ministry of Public 
Healthcare in Ecuador. RESULTS: Total costs in the lifetime horizon of treatment 
were $199,707.58 USD for the treatment sequence and $213,956.21 USD in the com-
parator sequence. Incremental costs for drug costs, administration costs, healthcare 
resources costs and other costs in the treatment sequence were -$11,881.02 USD, 
-$213.48 USD, -$460.56 USD and -1,694.60 USD respectively compared with the com-
parator sequence. Also the treatment sequence showed an incremental QALYs gain 
of 0.26 compared with the comparator sequence. CONCLUSIONS: Results suggest 
that the sequence treatment that includes the use of tofacitinib, represent a cost-
saving alternative when compared to the comparator sequence, in patients with 
Rheumatoid Arthritis (RA) who failed to DMARDS. This may represent savings for 
the Ministry of Public Healthcare in Ecuador.
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BACKGROUND: Rheumatoid Arthritis (RA) affects approximately 0.4% of the 
Latin American population over 16 years old. [1]. Many patients with rheumatoid 
arthritis (RA) do not respond adequately with disease-modifying antirheumatic 
drugs (DMARDs), being eligible for biological treatment available. OBJECTIVES: 
The objective was to evaluate the cost-effectiveness of Tofacitinib as second line 
vs continue using biological therapies in moderate RA after failure of DMARDs 
in Panama’s Ministry of Health (MINSA) in 2014. METHODS: The cost-effective-
ness model uses a patient-level simulation approach and assesses the economic 
and health benefits for the management of patients with RA who have an inad-
equate response to methotrexate. The model compares a treatment sequence 
with Tofacitinib followed by biologic treatments vs a sequence of biological 
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OBJECTIVES: The purpose of this study was to describe biologic discontinuation 
and assess the predictors of discontinuation in Canadian rheumatoid arthritis (RA) 
patients. METHODS: In this prospective cohort study, adult patients included in the 
RHUMADATA database with a diagnosis of RA and treated with at least one biologic 
since 2003 were selected. The RHUMADATA database includes clinical, laboratory 
and socioeconomic information of patients with rheumatic diseases followed in 
three Canadian rheumatology centers (Montreal, Quebec and Rimouski). Patients 
were followed for three years after therapy initiation or until treatment discontinu-
ation, as measured using pharmacy records. Time to discontinuation and predic-
tors of treatment discontinuation were explored using Cox proportional hazards 
models. RESULTS: A total of 623 eligible patients were treated with at least one 
biologic. The average age was 53.2 years (SD= 12.4), 77% were women and patients 
had been diagnosed for an average of 7.7 years. The average time on treatment for 
the first biologic agent was 1.7 years (SD= 2.1). In all, 233 (37%), 326 (52%), 405 (65%), 
and 438 (70%) patients had stopped their first biologic after 6, 12, 24, and 36 months, 
respectively. In time-to-event analyses (Cox proportional hazard models), type of 
work [part time vs. full time; hazard ratio (HR): 1.57; 95% confidence interval (CI): 
1.05-2.34] and income [$20,000 to $40,000 vs. less than $20,000 (HR: 1.35; 1.01-1.80) 
and $80,000 to $100,000 vs. less than $20,000 (HR: 2.16; 1.23-3.80)] were significantly 
associated with biologic discontinuation over the complete treatment duration. The 
number of disease-modifying antirheumatic drugs used (HR: 0.89; 0.80-0.99) and 
use of methotrexate (yes vs. no; HR: 0.80; 0.64-0.99) were associated with a reduced 
risk of biologic discontinuation. CONCLUSIONS: In this real-life Canadian study, 
high biologic discontinuation rates were observed. This study also suggests that 
many clinical and socioeconomic variables are predictors of biologic discontinu-
ation in RA patients.
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OBJECTIVES: Rheumatoid arthritis (RA) is a chronic inflammatory disorder that 
affects the lining of joints, causing painful swelling that can result in bone ero-
sion and joint deformity. Patient adherence to medications can help reduce or 
lessen inflammation; however, non-adherence and frequent switching are rec-
ognized problems in patients with RA. The objectives of this study are to bet-
ter understand patients’ reason(s) for being non-adherent and/or switching and 
physicians’ reasons for recommending a switch. METHODS: We extracted 300 
records for RA patients from a unique database of physician-patient interactions 
(RealHealthData). Using Atlas.ti, we analyzed these records to analyze trends for 
medication switches and/or non-adherence, i.e., when, why and how patients 
stopped or switched their medication. In addition, we analyzed physicians’ noted 
reasons for switching. RESULTS: On average, patients were 53 years old (±10). 
Patients’ functional disability was similar to the general RA population, with a 
noted variability of swelling and joint pain. The medications prescribed to the 
patients included: methotrexate (22%), Orencia (18%), Remicade (14%), Plaquenil 
(14%), Humira (13%) Enbrel (8%), Acterma (6%) and CellCept (5%). Patients’ reported 
reasons for switching and/or non-adherence included: increased pain/swelling 
(34%), feeling the medication is not working and/or continual progression of 
symptoms (35%) and adverse reaction to medication such as itching (11%) and 
GI complications (11%). Of the physicians who recommended switching, reasons 
for switching their patients’ medications included potential toxicities associated 
with drugs (46%) and observed disease progression (34%). CONCLUSIONS: It is 
critical to better understand patients’ and physicians’ reasons for switching medi-
cation for chronic disease like RA. The more we know about reasons for behavior, 
the more we can actively plan and organize research, development and outreach 
that is patient-centric and clinically meaningful. Our results demonstrate that 
using physician-patient interaction data can add tremendous value to outcomes 
researchers and healthcare decision makers.
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OBJECTIVES: To study the impact of rheumatoid arthritis on self-reported work 
productivity, disease severity and adherence in an employed population METHODS: 
A total of 1,041 patients with rheumatoid arthritis (RA) were identified from a list of 
3000 patients (18-65 years) from a Specialty Pharmacy database. Survey to the RA 
sample included the Work Productivity and Activity Impairment (WPAI) question-
naire, Health Assessment Questionnaire (HAQ) and Modified Morisky Scale (MMS). A 
demographic survey was also administered. Survey responses were linked to clinical 
measures obtained from the Specialty Pharmacy database. Univariate and multi-
variate regression analyses were conducted using SPSS version 22.0. RESULTS: The 
response rate was 30.45% (n= 317) and 57.4% (n= 174) reported as being employed. 
Mean age and disease duration of employed patients were 54.09+9.97 years and 
15.21+9.11 years, respectively. Employed patients were mostly female (66.5%), mar-
OBJECTIVES: Bisphosphonates are anti-osteoporosis medication. This study evalu-
ated the cost-effectiveness of the use of bisphosphonates in secondary prevention 
of hip fracture in a naturalistic setting from the payer perspective. METHODS: Using 
the 1997-2007 Taiwan’s National Health Insurance research database, we identified 
patients with the first-ever hospitalization experience for hip fracture between 
1998 and 2000. The patients who received bisphosphonates within the first year of 
hip fracture were grouped into “bisphosphonates cohort”; those who received no 
anti-osteoporosis medications were grouped into “untreated cohort”. The date of 
the hip fracture served as the date of cohort entry. The two cohorts were followed up 
for hip re-fracture and osteoporosis-related medical costs. A Cox regression model 
was used to compare the risk of hip re-fracture and a generalized linear model was 
used to compare the osteoporosis-related costs between the cohorts. RESULTS: 
Among 3,427 patients identified, 161 received bisphosphonates and 3,266 were 
left untreated. The mean follow-up period of the bisphosphonates cohort and the 
untreated cohort were 5.11 and 4.72 years. There was no significant difference in 
the risk of re-fracture between the two groups (adjusted hazard ratio = 1.24, 95% CI 
0.87-1.78, p= 0.227). However, the osteoporosis-related costs of the bisphosphonates 
cohort were significantly higher than the untreated cohort (the average incremen-
tal cost was 29,227 point values, 95% CI 14,890-43,564, p< 0.001). Further analysis 
showed that the use of bisphosphonates is likely to be cost-saving from a one-year 
perspective; the probability of cost-saving was 73.8%. CONCLUSIONS: This study 
found the use of bisphosphonates for the secondary prevention of hip fracture was 
cost-ineffective in a naturalistic setting.
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BACKGROUND: Rheumatoid arthritis (RA) is a common autoimmune disease associ-
ated with considerable morbidity rates and diminished quality of life. For patients 
who have an inadequate response to disease-modifying antirheumatic drugs 
(DMARDs), the use of biologic agents and JAK inhibitor has proved to be effective 
as second-line treatment. [1]. OBJECTIVES: To evaluate the cost-effectiveness of 
Tofacitinib as second line treatment vs using the standard biological therapies as 
second line treatments in patients with moderate RA after failure of DMARDs in 
Guatemala Health Care System (IGSS) in 2014. METHODS: A patient-level simula-
tion model was used to evaluate costs and health benefits. This cost-effectiveness 
model compares two sequences of treatments: one using Tofacitinib as second line 
treatment followed by biological therapies (Tofacitinib-Infliximab-Adalimumab-
Etanercept-Tocilizumab-Rituximab-salvage therapy ) and the other using the same 
biologic therapies scheme but excluding Tofacitinib; these schemes are defined 
according to experts opinion from IGSS [2]. All patients received concomitant treat-
ment with methotrexate. Model inputs are: age, weight, initial HAQ score, severe 
adverse events (SAE) and clinical response to short and long term treatment; rand-
omized controlled trials were used as a source information when local information 
was not available [3,4]. HAQ scores were used to calculate utilities, measured in 
QALYs [5,6,7]. Only direct costs were considered using institutional databases from 
2014. [8]. Annual discount rate was 5%, the time horizon is to lifetime. RESULTS: 
Total cost and total QALY per patient in a lifetime period are estimated to be $213,009 
and 8.83 QALY for the treatment sequence with Tofacitinib; $222,145 and 8.52 for 
treatment sequence with biologic therapy only. The cost savings from the treatment 
sequence with Tofacitinib are 15.2% in the first year, 15.0% in 5 year and 10.7% in 
ten years. CONCLUSIONS: For the IGSS, the sequence initiating with Tofacitinib is 
a cost-saving alternative compared with the standard biologic therapy
PMS59
aSSociation BEtwEEn oStEoarthritiS anD workPlacE aBSEntEEiSM
Menon J., Thomas III J.
Purdue University, West Lafayette, IN, USA
OBJECTIVES: Osteoarthritis is the most common form of arthritis, affecting 27 mil-
lion individuals in the United States. This study assessed incremental workplace 
absenteeism associated with osteoarthritis over one year. METHODS: Data from 
the 2011 Medical Expenditure Panel Survey (MEPS) was used for analyses. Sample 
inclusion criteria were being employed and at least eighteen years old. Individuals 
suffering from osteoarthritis were identified based on International Classification 
of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) diagnosis code of 715 in 
claims. Exclusion criteria were missing information on any variable. A zero inflated 
negative binomial regression was used with annual days missed at work as the 
response variable and a binary variable indicating osteoarthritis as the primary 
predictor. Covariates in the model adjusted for age, sex, education, race, marital 
status, occupation, region, insurance, hypertension, diabetes, anxiety, asthma, 
degree, hyperlipidemia and Charlson Comorbidity Index score. To account for the 
complex survey sample, sampling weights were incorporated in the model. Analyses 
were carried out using STATA for UNIX version 12.1 with an a priori alpha level of 
0.05. RESULTS: Among 10,597 individuals in the sample, 386 individuals had osteo-
arthritis. One-half of the sample was 47 years or younger, 54.43% were females, and 
70% were Caucasians. The expected number of days absent for individuals with 
osteoarthritis was 1.36 times the expected number of days absent for individuals 
without osteoarthritis (p= 0.038). Incremental annual days missed at work was 2.08 
days for individuals with osteoarthritis as compared to individuals without osteoar-
thritis (p= 0.037). Among covariates that were significant, expected number of days 
absent for individuals with hypertension was 1.37 times the expected number of 
days absent for those without hypertension (p< 0.01). The expected number of days 
absent for females was 1.54 times the expected number of days absent for males 
(p< 0.001). CONCLUSIONS: Osteoarthritis diagnosis is associated with significant 
incremental work absenteeism.
